{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T21:06:57Z","timestamp":1765487217059,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>The presence of autoantibodies against myelin oligodendrocyte glycoprotein (MOG) is a hallmark of MOG antibody-associated disease (MOGAD), a recently defined demyelinating disease entity presenting with core clinical features of optic neuritis, myelitis, and acute disseminated encephalomyelitis. Although MOG antibodies have also been described in a small number of patients with other conditions, including mental disorders, their prevalence and clinical specificity in patients with isolated psychotic symptoms remain unclear. Here, we screened sera from 262 patients with at least one psychotic episode and 166 control subjects for the presence of MOG antibodies of the immunoglobulin G (IgG) isotype with a live cell-based assay. Serum reactivity to additional antigens was assessed by immunohistochemistry. Four patients, representing 1.5% of the patient cohort, and one control individual, representing. 0.6% of the healthy control cohort, were seropositive for MOG-IgG antibodies. Of the four MOG-IgG seropositive patients, three experienced visual hallucinations. Overall, MOG antibodies were detected at a low frequency in patients with psychotic episodes. While we cannot exclude the possibility of false-positive results or seroconversion due to secondary myelin damage, the association with visual hallucinations in three out of four MOG-IgG seropositive patients may point toward an underlying autoimmune etiology.<\/jats:p>","DOI":"10.3389\/fneur.2025.1593042","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T19:02:08Z","timestamp":1752865328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms"],"prefix":"10.3389","volume":"16","author":[{"given":"Nikita A.","family":"van de Burgt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"Kulsvehagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Man\u00e9-Damas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Catherine","family":"Lecourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Monserrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita M.","family":"Vinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem \u0130.","family":"K\u00fc\u00e7\u00fckali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghua","family":"Zong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Gonz\u00e1lez-Vioque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole K.","family":"Leibold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Losen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdem","family":"T\u00fcz\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico J. M.","family":"van Beveren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Man\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob P. W.","family":"Rouhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese A. M. J.","family":"van Amelsvoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for Genetic Risk and Outcome of Psychosis (GROUP) Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Katrin","family":"Pr\u00f6bstel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Martinez-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"102348","DOI":"10.1016\/j.autrev.2019.102348","article-title":"Autoimmunity in psychotic disorders. Where we stand, challenges and opportunities","volume":"18","author":"Man\u00e9-Damas","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41398-020-00989-x","article-title":"Cognitive impact of neuronal antibodies: encephalitis and beyond","volume":"10","author":"Gibson","year":"2020","journal-title":"Transl Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.schres.2020.12.038","article-title":"The search for an autoimmune origin of psychotic disorders: prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens","volume":"228","author":"Hoffmann","year":"2021","journal-title":"Schizophr Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/jamapsychiatry.2019.3679","article-title":"Absence of autoantibodies against neuronal surface antigens in sera of patients with psychotic disorders","volume":"77","author":"Hoffmann","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41398-020-01083-y","article-title":"Novel neuronal surface autoantibodies in plasma of patients with depression and anxiety","volume":"10","author":"Zong","year":"2020","journal-title":"Transl Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1017\/neu.2021.29","article-title":"Anti-MOG autoantibody-associated schizophreniform psychosis","volume":"34","author":"von Zedtwitz","year":"2022","journal-title":"Acta Neuropsychiatr"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"100073","DOI":"10.1016\/j.nerep.2022.100073","article-title":"Psychiatric manifestations of anti-MOG antibody disease","volume":"2","author":"Singh","year":"2022","journal-title":"Neuroimmunol Rep"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1212\/WNL.0000000000204258","article-title":"Novel psychiatric manifestations of anti-MOG antibody disease (P10-5.031)","volume":"100","author":"Singh","year":"2023","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1176\/appi.neuropsych.18010005","article-title":"Anti-N-methyl-D-aspartate receptor encephalitis: a review of psychiatric phenotypes and management considerations: a report of the American neuropsychiatric association committee on research","volume":"31","author":"Sarkis","year":"2019","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/mpr.1352","article-title":"GROUP investigators","volume":"21","author":"Korver","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.rpsm.2014.05.004","article-title":"Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM study): rationale, objectives, design and sample description","volume":"7","author":"Pina-Camacho","year":"2014","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2023.2523","article-title":"Immunoglobulin a antibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with central nervous system demyelination","volume":"80","author":"AB","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Probstel","year":"2011","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ana.24189","article-title":"Seroprevalence of autoantibodies against brain antigens in health and disease","volume":"76","author":"Dahm","year":"2014","journal-title":"Ann Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ajo.2020.07.014","article-title":"Population-based incidence of optic neuritis in the era of Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies","volume":"220","author":"Hassan","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","article-title":"MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"20552173211022767","DOI":"10.1177\/20552173211022767","article-title":"Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients","volume":"7","author":"Held","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2018.03.019","article-title":"An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis","volume":"320","author":"Zhou","year":"2018","journal-title":"J Neuroimmunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.msard.2018.12.017","article-title":"A rare concurrence: antibodies against myelin oligodendrocyte glycoprotein and N-methyl-d-aspartate receptor in a child","volume":"28","author":"Sarigecili","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.11648\/j.ajpn.20190701.12","article-title":"Peduncular hallucinosis and overlapping antiganglioside antibody syndrome","volume":"7","author":"Demas","year":"2019","journal-title":"Am J Psychiatry Neurosci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1016\/j.nerep.2021.100022","article-title":"Acute onset visual and auditory hallucinations: an unusual case of pediatric-onset multiple sclerosis","volume":"1","author":"Rolfes","year":"2021","journal-title":"Neuroimmunol Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1177\/1352458510365157","article-title":"Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study","volume":"16","author":"Lo Fermo","year":"2010","journal-title":"Mult Scler J"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1212\/WNL.98.18_supplement.2429","article-title":"MOG antibody-associated disease manifesting as MRI-negative encephalitis: a case report and literature review P16-1.004","volume":"98","author":"Anson","year":"2022","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.47936\/encephalitis.2023.00234","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as unilateral cerebral cortical encephalitis: a case report","volume":"4","author":"An","year":"2024","journal-title":"Encephalitis"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1593042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T19:02:09Z","timestamp":1752865329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1593042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":31,"alternative-id":["10.3389\/fneur.2025.1593042"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1593042","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"article-number":"1593042"}}